NLS Pharma Business

Vienna-based HeartBeat.bio and Stockholm-based Cubase Bio have been awarded roughly EUR 1 million in Eurostars funding to develop a 3D spatial profiling method for studying myocardial fibrosis and heart failure, combining human cardiac organoids with true 3D spatial transcriptomics technology.

Klaria has entered a collaboration agreement with RTHS to combine RTHS's sensor-based measurements of blood flow dynamics with Klaria's approved migraine treatment, aiming to detect migraine attacks before symptoms set in.

European regulators have validated Chiesi's submissions for two next-generation propellant inhalers, part of the biopharma company's shift toward lower-carbon respiratory products.

Enhertu in combination with pertuzumab has been approved in the European Union for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer – the first new regimen in this setting in more than a decade, AstraZeneca and Daiichi Sankyo announced.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer — the first new regimen in more than ten years for this patient group.

Uppsala-based Readily Diagnostics has received a grant of approximately USD 970,000 (about SEK 9 million) from the Gates Foundation to develop a low-cost point-of-care test for chlamydia, gonorrhea and trichomoniasis, aimed at low-resource settings.